SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/14/20 Cell MedX Corp. 10-Q 2/29/20 67:2.2M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 353K 6: EX-10.60 Loan Agreement and Note Payable Dated December 3, HTML 26K 2019, Among Cell Medx Corp. and Longview Investment Limited 7: EX-10.61 Loan Agreement and Note Payable Dated January 6, HTML 26K 2020, Among Cell Medx Corp. and Longview Investment Limited 8: EX-10.62 Loan Agreement and Note Payable Dated January 9, HTML 26K 2020, Among Cell Medx Corp. and Longview Investment Limited 9: EX-10.63 Loan Agreement and Note Payable Dated January 31, HTML 26K 2020, Among Cell Medx Corp. and Longview Investment Limited 10: EX-10.65 Loan Agreement and Note Payable Dated February 17, HTML 26K 2020, Among Cell Medx Corp. and Longview Investment Limited 11: EX-10.66 Loan Agreement and Note Payable Dated March 4, HTML 26K 2020, Among Cell Medx Corp. and Longview Investment Limited 12: EX-10.67 Loan Agreement and Note Payable Dated March 25, HTML 26K 2020, Among Cell Medx Corp. and Longview Investment Limited 2: EX-31.1 Certification -- §302 - SOA'02 HTML 24K 3: EX-31.2 Certification -- §302 - SOA'02 HTML 24K 4: EX-32.1 Certification -- §906 - SOA'02 HTML 21K 5: EX-32.2 Certification -- §906 - SOA'02 HTML 21K 26: R1 Document and Entity Information HTML 69K 41: R2 Condensed Consolidated Balance Sheets HTML 99K 63: R3 Condensed Consolidated Balance Sheets - HTML 28K Parenthetical 30: R4 Condensed Consolidated Statements of Operations HTML 92K 27: R5 Condensed Consolidated Statement of Stockholders' HTML 69K Deficit 42: R6 Condensed Consolidated Statements of Cash Flows HTML 94K 64: R7 Organization and Nature of Operations HTML 29K 33: R8 Related Party Transactions Disclosure HTML 36K 25: R9 Inventory Disclosure HTML 25K 19: R10 Other Current Assets Disclosure HTML 23K 37: R11 Equipment Disclosure HTML 28K 58: R12 Unearned Revenue Disclosure HTML 37K 52: R13 Revenue Disclosure HTML 27K 20: R14 Notes and Advances Payable Disclosure HTML 43K 38: R15 Share Capital Disclosure HTML 49K 59: R16 Subsequent Event Disclosure HTML 26K 53: R17 Organization and Nature of Operations: Going HTML 25K Concern (Policies) 21: R18 Related Party Transactions Disclosure: Schedule of HTML 28K Amounts Due to Related Parties (Tables) 36: R19 Related Party Transactions Disclosure: Schedule of HTML 27K Transactions with Related Parties (Tables) 66: R20 Equipment Disclosure: Amortization schedule for HTML 27K the equipment (Tables) 45: R21 Unearned Revenue Disclosure: Changes to Unearned HTML 28K Revenue (Tables) 28: R22 Unearned Revenue Disclosure: Schedule of Loss on HTML 25K Reacquisition of Distribution Rights (Tables) 34: R23 Revenue Disclosure: Schedule of Revenue and HTML 27K Associated Costs (Tables) 67: R24 Notes and Advances Payable Disclosure: Schedule of HTML 35K Short-term Loans and Advances Outstanding (Tables) 46: R25 Share Capital Disclosure: Schedule of Stock Option HTML 29K Activity (Tables) 29: R26 Share Capital Disclosure: Schedule of Stock HTML 27K Options Outstanding (Tables) 35: R27 Share Capital Disclosure: Schedule of Warrant HTML 26K Activity (Tables) 65: R28 Share Capital Disclosure: Schedule of Warrant HTML 31K Details (Tables) 48: R29 Organization and Nature of Operations: Going HTML 25K Concern (Details) 51: R30 Related Party Transactions Disclosure: Schedule of HTML 34K Amounts Due to Related Parties (Details) 56: R31 Related Party Transactions Disclosure: Schedule of HTML 31K Transactions with Related Parties (Details) 40: R32 Inventory Disclosure (Details) HTML 37K 23: R33 Other Current Assets Disclosure (Details) HTML 25K 50: R34 Equipment Disclosure: Amortization schedule for HTML 32K the equipment (Details) 55: R35 Unearned Revenue Disclosure: Changes to Unearned HTML 34K Revenue (Details) 39: R36 Unearned Revenue Disclosure (Details) HTML 36K 22: R37 Unearned Revenue Disclosure: Schedule of Loss on HTML 30K Reacquisition of Distribution Rights (Details) 49: R38 Revenue Disclosure: Schedule of Revenue and HTML 41K Associated Costs (Details) 57: R39 Notes and Advances Payable Disclosure: Schedule of HTML 42K Short-term Loans and Advances Outstanding (Details) 44: R40 Notes and Advances Payable Disclosure (Details) HTML 39K 62: R41 Share Capital Disclosure (Details) HTML 40K 32: R42 Share Capital Disclosure: Schedule of Stock Option HTML 30K Activity (Details) 24: R43 Share Capital Disclosure: Schedule of Stock HTML 32K Options Outstanding (Details) 43: R44 Share Capital Disclosure: Schedule of Warrant HTML 28K Activity (Details) 61: R45 Share Capital Disclosure: Schedule of Warrant HTML 38K Details (Details) 31: R46 Subsequent Event Disclosure (Details) HTML 31K 60: XML IDEA XML File -- Filing Summary XML 110K 54: EXCEL IDEA Workbook of Financial Reports XLSX 46K 13: EX-101.INS XBRL Instance -- cmxc-20200229 XML 571K 15: EX-101.CAL XBRL Calculations -- cmxc-20200229_cal XML 65K 16: EX-101.DEF XBRL Definitions -- cmxc-20200229_def XML 270K 17: EX-101.LAB XBRL Labels -- cmxc-20200229_lab XML 461K 18: EX-101.PRE XBRL Presentations -- cmxc-20200229_pre XML 419K 14: EX-101.SCH XBRL Schema -- cmxc-20200229 XSD 116K 47: ZIP XBRL Zipped Folder -- 0001393905-20-000119-xbrl Zip 56K
ex-10.61 |
LOAN AGREEMENT
Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on January 6, 2020.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from January 6, 2020 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
LENDER | BORROWER |
Longview Investment Limited | Cell MedX Corp. |
|
|
Per: |
Per: |
|
|
|
|
/s/ Rick Donaldson | /s/ Yanika Silina |
Name: Rick Donaldson | Yanika Silina, CFO |
PROMISSORY NOTE
Principal Amount: USD$10,000 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Longview Investment Limited (the “Lender”) the sum of $10,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from January 6, 2020 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 4/14/20 | None on these Dates | ||
For Period end: | 2/29/20 | |||
1/6/20 | ||||
List all Filings |